May 6th 2024
During a Case-Based Roundtable® event, Ulka Vaishampayan, MBBS, discussed the safety and quality-of-life data for ipilimumab plus nivolumab in patients with advanced renal cell carcinoma in the second article of a 2-part series.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Advances in Subsequent Therapies Shake Up Sequencing of ccRCC Treatment
April 25th 2024With the approval of belzutifan and other newer data for treating patients with recurrent renal cell carcinoma, the state of subsequent therapies is advancing beyond the reuse of frontline options with impacts on duration of response and quality of life.
Read More
Deciding Factors for Front-Line Therapy in Metastatic RCC
April 17th 2024During a Case-Based Roundtable® event, Shilpa Gupta, MD, led a discussion on what factors influence physician decision making for frontline therapy in patients with metastatic renal cell carcinoma in the first article of a 2-part series.
Read More
Long-Term Ipi/Nivo RCC Data Show Durability Across Risk Groups
April 12th 2024During a Case-Based Roundtable® event, Ulka Vaishampayan, MBBS, discussed the 8-year follow-up data of ipilimumab plus nivolumab in patients with advanced renal cell carcinoma In the first article of a 2-part series.
Read More
George Discusses Potency of VEGF TKIs in Advanced Renal Cell Carcinoma
March 22nd 2024During a Case-Based Roundtable® event, Saby George, MD, discussed the case of a patient with clear cell renal cell carcinoma who progressed after left nephrectomy followed by treatment with axitinib plus pembrolizumab at recurrence.
Read More
Unique Challenges of Using IO/TKI Combinations in Metastatic RCC
March 12th 2024During a Targeted Oncology™ Case-Based Roundtable™ event, Robert J. Motzer, MD, asked participants to share their experiences using nivolumab plus cabozantinib in patients with advanced renal cell carcinoma. This is the second of 2 articles based on this event.
Read More
Evolving Evidence Guides Treatment Selection for Favorable-Risk mRCC
March 6th 2024During a Targeted Oncology™ Case-Based Roundtable™ event, Rana McKay, MD, moderated a discussion on key takeaways from frontline combination trial data in patients with metastatic renal cell carcinoma. This is the second of 2 articles based on this event.
Read More
Guideline Recommendation Favors Doublet Over Triplet Therapy in ccRCC
February 28th 2024New guideline favors doublet therapy over triplet for metastatic renal clear cell cancer due to lower toxicity. COSMIC-313 trial shows improved progression-free survival with triplet therapy but significant adverse events.
Read More
Risk Groups Vital to Interpreting Results of RCC Immunotherapy Trials
February 21st 2024During a Targeted Oncology™ Case-Based Roundtable™ event, Robert J. Motzer, MD, examined the impact of the CheckMate 214 and CheckMate 9ER trials of nivolumab/ipilimumab and nivolumab/cabozantinib in patients with advanced renal cell carcinoma. This is the first of 2 articles based on this event.
Read More
Risk Stratification Influences Choice of Frontline IO/TKI Regimen in mRCC
February 13th 2024During a Targeted Oncology™ Case-Based Roundtable™ event, Rana McKay, MD, moderated a discussion on what role risk stratification plays in selecting frontline therapy for a patient with metastatic renal cell carcinoma. This is the first of 2 articles based on this event.
Read More